No Data
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market
Here's How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 5 Years
Maxim Group Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $120
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating
A Quick Look at Today's Ratings for Viking Therapeutics(VKTX.US), With a Forecast Between $90 to $125